Melanoma Clinical Trial
Official title:
Melanoma Simulation Model With Smartphone Devices: Training Physicians to Perform Opportunistic Surveillance for Early Detection of Melanoma
The specific aim of this study is to determine if interactive touchscreen-based learning with deliberate practice modules can enhance the retention of life-saving medical skills when incorporated into medical training curricula. We will analyze the retention and confidence of screening skills by comparing outcomes on pretest and posttest in each arm.
Age-adjusted melanoma incidence among Caucasians has risen from 7.5 to 21.9 cases per
100,000 representing an increase of nearly 200% over 30 years. In contrast to other cancers
(i.e. colorectal, prostate, cervical), melanoma is detected by intentional visual skin
inspection. Intentional screening is the deliberate visual inspection of all cutaneous
surfaces. However, fewer than 30% of primary care physicians (PCPs) reported training in
skin cancer during their medical education. Early detection of melanoma by PCPs cannot be
expected to improve without addressing both the PCPs' lack of training and their low
confidence in examination skills pertaining to pigmented lesion exams. A focused
intervention is required to improve PCPs' early detection of melanoma and mitigate the
near-term consequences of an aging US population.
Opportunistic surveillance requires skills in both unaided visual inspection of the skin and
in dermoscopy of lesions. Dermoscopy—a hand-held magnifying device that assists with
diagnosis—reduces the number of unnecessary biopsies and improves the clinical sensitivity
of diagnosing melanoma. Studies show that Australian PCPs trained to use a "three-point
checklist of dermoscopy," developed biopsy ratios of benign to malignant lesions of 8:1 in
the general population, which is comparable to dermatologists using dermoscopy. In 2009, the
American Academy of Family Physicians held their first dermoscopy course at their Annual
Scientific Meeting, and there is continuing demand for similar courses. By making dermoscopy
customary for PCPs, PCPs will be able to detect melanomas opportunistically and render care
to the at-risk population of elderly for whom they provide care. Smart-touchscreen
technologies can potentially provide a safe environment for medical trainees to learn
procedural and screening skills that are rarely available opportunities in the clinic. As
such, these technologies may lead to better health outcomes in future populations.
In this study, eighty 3rd year medical and thirty 1st year physician's assistant students
participate in a visual screening and dermoscopy curriculum aimed at improving the retention
rate of the learned clinical skills. After a didactic lecture on melanoma screening,
participants are randomized to either a control or an experimental study arm for the
clinical skills workshop. The control arm represents our previously published clinical
skills training workshop (IRB STU 0002705) in which participants interact with a simulated
patient model presenting with pigment lesions and review dermoscopy images on a projector
screen. In the experimental arm, the projector-based learning approach is replaced with a
handheld touchscreen device (smartphone) preloaded with interactive melanoma screening
tutorial. The smartphone provides instant feedback and remediation of improper clinical
management decisions. Across both groups, all learning content remains similar. Further
deliberate practice questions provided to the control arm are standardized while the
experimental arm's questions are individualized based on weaknesses determined in the
smartphone software.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|